eligibility_summary
Eligible: Adults 18–80, ECOG 0–2, consent/compliant, histologically confirmed DLBCL with evaluable disease, not in CR or relapsed after second-line therapy, contraception during and 6 months after (women need negative pregnancy test). Exclude: CNS or primary mediastinal subtypes, severe/uncontrolled comorbidities, active autoimmune disease or prior allogeneic transplant, active infection ≤14 days, recent/ongoing trials, other safety risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06832228 tests the PPR regimen (pomalidomide + rituximab + anti–PD-1 antibody) as third-line or later therapy for DLBCL. Pomalidomide is an oral immunomodulatory drug (IMiD) that binds cereblon E3 ligase, degrading IKZF1/3 (Ikaros/Aiolos), enhancing T-cell and NK-cell activation and cytokines (e.g., IL-2, IFN-γ), and exerting anti-proliferative and anti-angiogenic effects. Rituximab is an anti-CD20 monoclonal antibody that targets CD20 on B cells to induce ADCC, CDC, and apoptosis. The anti–PD-1 antibody is a checkpoint inhibitor that blocks PD-1 on T cells to reverse PD-L1/PD-L2–mediated exhaustion and restore antitumor immunity. Targets/pathways: CD20+ malignant B cells, PD-1/PD-L1 checkpoint, cereblon–IKZF axis, activation of cytotoxic T cells and NK cells, tumor microenvironment/angiogenesis. Single-arm, 4–6 cycles with optional maintenance.